- •Table of Contents
- •Copyright
- •Contributors
- •How to Use this Study Guide
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •4: Outcomes Research
- •Questions
- •Answers
- •5: Core Principles of Perioperative Care
- •Questions
- •Answers
- •Questions
- •Answers
- •7: Principles of Urologic Endoscopy
- •Questions
- •Answers
- •8: Percutaneous Approaches to the Upper Urinary Tract Collecting System
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •12: Infections of the Urinary Tract
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •15: Sexually Transmitted Diseases
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •20: Principles of Tissue Engineering
- •Questions
- •Answers
- •Questions
- •Answers
- •22: Male Reproductive Physiology
- •Questions
- •Answers
- •Questions
- •Answers
- •24: Male Infertility
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •28: Priapism
- •Questions
- •Answers
- •Questions
- •Answers
- •30: Surgery for Erectile Dysfunction
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •34: Neoplasms of the Testis
- •Questions
- •Answers
- •35: Surgery of Testicular Tumors
- •Questions
- •Answers
- •36: Laparoscopic and Robotic-Assisted Retroperitoneal Lymphadenectomy for Testicular Tumors
- •Questions
- •Answers
- •37: Tumors of the Penis
- •Questions
- •Answers
- •38: Tumors of the Urethra
- •Questions
- •Answers
- •39: Inguinal Node Dissection
- •Questions
- •Answers
- •40: Surgery of the Penis and Urethra
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •47: Renal Transplantation
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •50: Upper Urinary Tract Trauma
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •53: Strategies for Nonmedical Management of Upper Urinary Tract Calculi
- •Questions
- •Answers
- •54: Surgical Management for Upper Urinary Tract Calculi
- •Questions
- •Answers
- •55: Lower Urinary Tract Calculi
- •Questions
- •Answers
- •56: Benign Renal Tumors
- •Questions
- •Answers
- •57: Malignant Renal Tumors
- •Questions
- •Answers
- •Questions
- •Answers
- •59: Retroperitoneal Tumors
- •Questions
- •Answers
- •60: Open Surgery of the Kidney
- •Questions
- •Answers
- •Questions
- •Answers
- •62: Nonsurgical Focal Therapy for Renal Tumors
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •66: Surgery of the Adrenal Glands
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •71: Evaluation and Management of Women with Urinary Incontinence and Pelvic Prolapse
- •Questions
- •Answers
- •72: Evaluation and Management of Men with Urinary Incontinence
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •76: Overactive Bladder
- •Questions
- •Answers
- •77: Underactive Detrusor
- •Questions
- •Answers
- •78: Nocturia
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •82: Retropubic Suspension Surgery for Incontinence in Women
- •Questions
- •Answers
- •83: Vaginal and Abdominal Reconstructive Surgery for Pelvic Organ Prolapse
- •Questions
- •Answers
- •Questions
- •Answers
- •85: Complications Related to the Use of Mesh and Their Repair
- •Questions
- •Answers
- •86: Injection Therapy for Urinary Incontinence
- •Questions
- •Answers
- •87: Additional Therapies for Storage and Emptying Failure
- •Questions
- •Answers
- •88: Aging and Geriatric Urology
- •Questions
- •Answers
- •89: Urinary Tract Fistulae
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •92: Tumors of the Bladder
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •95: Transurethral and Open Surgery for Bladder Cancer
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •99: Orthotopic Urinary Diversion
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Answers
- •Questions
- •Answers
- •108: Prostate Cancer Tumor Markers
- •Questions
- •Answers
- •Questions
- •110: Pathology of Prostatic Neoplasia
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •114: Open Radical Prostatectomy
- •Questions
- •Answers
- •Questions
- •Answers
- •116: Radiation Therapy for Prostate Cancer
- •Questions
- •Answers
- •117: Focal Therapy for Prostate Cancer
- •Questions
- •Answers
- •Questions
- •Answers
- •119: Management of Biomedical Recurrence Following Definitive Therapy for Prostate Cancer
- •Questions
- •Answers
- •120: Hormone Therapy for Prostate Cancer
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •124: Perinatal Urology
- •Questions
- •Answers
- •Questions
- •Answers
- •126: Pediatric Urogenital Imaging
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •133: Surgery of the Ureter in Children
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •137: Vesicoureteral Reflux
- •Questions
- •Answers
- •138: Bladder Anomalies in Children
- •Questions
- •Answers
- •139: Exstrophy-Epispadias Complex
- •Questions
- •Answers
- •140: Prune-Belly Syndrome
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •144: Management of Defecation Disorders
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •147: Hypospadias
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •152: Adolescent and Transitional Urology
- •Questions
- •Answers
- •Questions
- •Answers
- •154: Pediatric Genitourinary Trauma
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
62
Nonsurgical Focal Therapy for Renal Tumors
Chad R. Tracy; Jeffrey A. Cadeddu
Questions
1.Nephron-sparing surgery (partial nephrectomy):
a.is the predominant treatment modality used in the United States for the management of small renal masses.
b.offers equivalent cancer-specific and overall survival compared with radical nephrectomy.
c.when performed laparoscopically, it is associated with fewer complications than radiofrequency ablation (RFA) or cryoablation.
d.offers metastatic recurrence-free survival and cancer-specific survival similar to that of radiofrequency ablation and cryoablation.
e.was not impacted by the advent of hand-assisted laparoscopic radical nephrectomy.
2.With regard to deciding on a particular ablation modality, which of the following should be considered?
a.RFA is associated with less postoperative hemorrhage than cryoablation.
b.Both RFA and cryoablation are subject to "heat sink."
c.The American Urological Association (AUA) guidelines currently recommend consideration of ablation for primary treatment of T1a renal tumors, even for younger, healthier patients, with the understanding that recurrence rates may be higher and salvage procedure more difficult.
d.All of the above
e.Both a and b are true
3.The critical treatment temperature threshold during cryoablation at which
irreparable cell damage is achieved is:
a.0° C.
b.− 60° C.
c.− 20° C.
d.− 40° C.
e.− 19.4° C.
4.Critical parameters for successful renal cryosurgery include:
a.a double freeze-thaw cycle.
b.achieving a critical target temperature.
c.treatment under real-time image guidance.
d.treatment to beyond 1 cm of the targeted lesion.
e.all of the above.
5.Compared with renal cryoablation, the primary disadvantage of RFA is:
a.higher risk of hemorrhage following RFA.
b.inability to use RFA laparoscopically.
c.inability to monitor treatment under image guidance.
d.inferior cancer-specific survival.
e.none of the above.
6.Recent meta-analyses have demonstrated:
a.higher local recurrence rates with ablative technologies when compared with partial or radical nephrectomy.
b.no evidence for the superiority of one ablation technology versus the other with regard to oncologic outcomes or complications.
c.a lack of uniformity regarding evaluation, patient selection, treatment, and follow-up of patients undergoing renal tumor ablation.
d.fewer complications with renal tumor ablation compared with extirpative treatments.
e.all of the above.
7.The most important technique to increase the size of RF lesions is:
a.using higher RF currents.
b.applying RF currents faster to achieve better heating.
c.clamping hilar vessels.
d.reducing impedance by improving current conductivity.
e.using "dry" RFA.
8.Regarding high-intensity focused ultrasonography (HIFU), which of the following is TRUE?
a.Preliminary data suggest equivalent oncologic outcomes with HIFU
when compared with alternative ablative technologies or extirpative options.
b.HIFU acts through local thermal and cavitary processes to generate tissue temperatures in excess of 65° C.
c.Animal and human studies have demonstrated consistent tissue necrosis following treatment.
d.The most commonly cited complication following HIFU for the treatment of renal lesions is post-treatment hemorrhage.
e.Because renal HIFU is performed under real-time image guidance, targeting is not significantly impacted by respiratory movement.
9.Following tumor ablation, the most reliable method of documenting treatment success is:
a.biopsy of the treatment area with hematoxylin and eosin (H&E) staining.
b.biopsy of the treatment area with reduced nicotinamide adenine dinucleotide (NADH) diaphorase staining.
c.follow-up computed tomography (CT) or magnetic resonance imaging (MRI) with contrast that demonstrates complete loss of contrast enhancement and stable or decreased size of the treated area.
d.follow-up CT or MRI without contrast that demonstrates a decrease in size of the treated area.
e.all of the above.
Answers
1.d. Offers metastatic recurrence-free survival and cancer-specific survival similar to that of radiofrequency ablation and cryoablation. Nephronsparing surgery is considered the gold standard treatment for small renal masses but is underused in the United States. Partial nephrectomy offers equivalent oncologic outcomes when compared with radical nephrectomy and demonstrates superior renal functional preservation. Laparoscopic partial nephrectomy offers excellent cancer-specific end points but is technically challenging and is associated with significant complications. Cryoablation and radiofrequency ablation are associated with significantly fewer complications than laparoscopic partial nephrectomy. There is no significant difference in metastatic recurrence-free survival between extirpative and ablative treatments. Cancer-specific survival (CSS) following RFA is
comparable to laparoscopic partial nephrectomy. CSS is comparable between open partial nephrectomy and both RFA and cryoablation.
Preliminary studies suggest that the technical ease and minimal morbidity of hand-assisted laparoscopic nephrectomy may ultimately lead to fewer nephron-sparing procedures.
2.e. Both a and b are true.
3.d. − 40° C. Experimental evidence suggests that irreversible cellular damage is achieved in normal renal parenchyma at − 19.4° C. However, tumor cells require lower treatment temperatures to achieve uniform cellular necrosis.
The recommended treatment temperature during renal cryosurgery is − 40° C.
4.e. All of the above. Animal studies have demonstrated that a single freezethaw cycle is inferior to a double freeze-thaw cycle with respect to adequacy of tissue ablation and local tumor control. As mentioned, complete cellular necrosis is consistently achieved at a targeted temperature of − 40° C. Campbell and colleagues (1998)* demonstrated that the aforementioned threshold temperature of − 40° C was achieved 3.1 mm inside the edge of the evolving ice ball. To guarantee that the tumor is completely ablated with a margin of normal tissue, the ice ball is generally carried 5 to 10 mm beyond the edge of the tumor when viewed under real-time imaging.
5.c. Inability to monitor treatment under image guidance. The primary disadvantage when employing RFA for the treatment of renal lesions is difficulty in monitoring treatment under real-time image guidance. The risk of hemorrhage is higher with cryoablation. RFA may be employed laparoscopically, percutaneously, or openly. Cancer-specific survival is equivalent between RFA and cryoablation.
6.e. All of the above. Three recent meta-analyses evaluated outcomes following partial nephrectomy, radical nephrectomy, cryoablation, and RFA for the treatment of small renal masses. Both RFA and cryoablation demonstrated higher local recurrence rates when compared with partial or radical nephrectomy. However, the majority of published studies on cryoablation and RFA have enrolled small numbers of patients and used disparate operative and follow-up protocols. The pathology is either not obtained or is difficult to interpret, and the reliability of radiographic imaging remains unknown. Although the aggregate duration of follow-up is too short to derive irrefutable conclusions, treatment outcomes with cryoablation and RFA appear comparable. In general, complications occur with equal or less frequency with tumor ablation when compared with partial or radical
nephrectomy.
7.d. Reducing impedance by improving current conductivity. The electrically conductive agent facilitates the delivery of energy from the electrode to surrounding tissue, rendering it a much larger, "virtual" electrode. Impedance remains lower, and larger volumes are ablated. One technique to accomplish this is to employ saline-cooled electrodes, which reduce charring at the tip of the electrode and thereby reduce impedance.
8.b. HIFU acts through local thermal and cavitary processes to generate tissue temperatures in excess of 65° C. The use of HIFU in the treatment of small renal masses remains investigational. Experimental data has demonstrated "skip" lesions following treatment, which have been attributed to targeting obstacles, including acoustic interference and respiratory movement. Skin burns have been reported in as many as 10% of patients.
9.c. Follow-up computed tomography (CT) or magnetic resonance imaging (MRI) with contrast that demonstrates complete loss of contrast enhancement and stable or decreased size of the treated area. Complete loss of contrast enhancement on follow-up CT or MRI has been considered a sign of complete tissue destruction. Following cryoablation, the treated area demonstrates a decrease in size of approximately 50% in the year following treatment. Following RFA, the treated area may not demonstrate a decrease in size. Any increase in size following treatment should be viewed as an ominous sign, and intervention should be directed accordingly. Postablative biopsy, although helpful, yields ambiguous results following RFA. Its use and interpretation remain controversial.
Chapter review
1.Currently, a double freeze-thaw cycle is suggested for cryotherapy with a period of time during each cycle in which the temperature is maintained at − 40° C.
2.Radiofrequency waves generate heat by causing ionic agitation in the tissue through which they pass; charring at the probe tip prevents adequate conduction of the wave from the probe into tissue; to prevent heat at the probe becoming excessive with resultant charring, the probes are cooled.
3.CT or MRI is used to follow patients after ablative therapy. There should be a complete lack of contrast enhancement at the tumor site. Successful cryoablation on follow-up imaging often reveals up to a 50% reduction
in size of the lesion. RF ablation followed over the long term often shows a slight reduction in size and cavitation.
4.The tumor should be biopsied to confirm its malignant nature before ablative therapy is performed.
5.The most common complication following cryoablation is hemorrhage; a serious complication following radiofrequency ablation is ureteral/collecting system injury. Bleeding is less common following radiofrequency ablation.
6.High-intensity focused ultrasonography generates heat by focusing the ultrasound waves at a point; unfortunately, skin burns are a common complication of this technology.
7.There is no significant difference in metastatic recurrence-free survival between extirpative and ablative treatments. Cancer-specific survival (CSS) following RFA is comparable to laparoscopic partial nephrectomy. CSS is comparable between open partial nephrectomy and both RFA and cryoablation.
* Sources referenced can be found in Campbell-Walsh Urology, 11th Edition, on the Expert Consult website.